Why This Pharmaceutical Stock Jumped Almost 100% This Week
A mid-cap biotech surged close to 100% on news of a major deal and regulatory progress. This guide breaks down what h...
Identify the right moments to revise your spending plan so your budget remains responsive to changes in income and expenses.
22,044 articlesA mid-cap biotech surged close to 100% on news of a major deal and regulatory progress. This guide breaks down what h...
A tariff reversal can trigger a short-lived stock market surge, but gains often fade as details unfold. This guide ex...
Energy Transfer has kicked off the year with impressive momentum and a raised outlook. This article breaks down why t...
A niche corner of the tech market has seen attention turn toward optical component makers. This article explains why ...
When allegations collide with privacy, financial planning and legal strategy collide too. This piece breaks down why ...
As the calendar closes on 2025, Ascendis (ASND) faces the final earnings closeout with questions about cash, pipeline...
This in-depth alphabet stock analysis: final piece breaks down Alphabet's earnings, competitive position, and the act...
A deep dive into mib: jean eric salata, chair of EQT, exploring how cross-cultural experience and AI-driven infrastru...
When software stocks dip, smart investors look for durable moats, growing cash flow, and AI-enabled growth. This guid...
Grail stock showed a notable bounce after several tough sessions tied to trial updates. This piece breaks down what’s...
Investors weighed the promise of Milestone Pharmaceuticals against the realities of a high-stakes biotech market. Thi...
A new AI narrative is taking shape. Nvidia Jensen Huang Just outlined a path where autonomous AI agents could transfo...